ALK-abello A/S Class B ALK_B

Inside Information Agreement provides long-term expanded access to Catalent's fast-dissolving (Zydis®) tablet formulation technology.Supply robustness secured with prioritised manufacturing capacity increase of ~40% to 1.1 billion tablets annually from early 2030s.Over three years, ALK to invest DKK 500 million in capacity at Catalent. ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that it has expanded its long-standing contract manufacturing partnership with Catalent, Inc. ("Catalent"

ALK-Abelló (CPSE:ALK B) has reshuffled its top ranks, appointing Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy, effective 1 October 2026, as investors weigh what this leadership shift could mean. Against this backdrop, ALK-Abelló’s recent 7-day share price return of 4.52% comes after a 30-day share price decline of 6.94% and a 90-day share price drop of 21.48%, while the 3-year total shareholder return of 151.90% points to strong longer term...

Tina A. Olesen, Executive Vice President for Corporate, Portfolio and Product Strategy Tina A. Olesen has been appointed Executive Vice President for Corporate, Portfolio and Product Strategy at ALK, effective 1 October 2026. ALK today announced the appointment of Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy (CPPS), effective 1 October 2026. Tina succeeds Jacob Glenting, who headed CPPS before being appointed Executive Vice President for Research &

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the company’s Executive Vice President and CFO, Claus Steensen Sølje, is scheduled to participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City taking place from 14 - 16 September 2026 on Monday, 14 September 2026, at 3.20 PM EDT. Representatives of the company will be available for meetings at the conference. ALK-Abelló A/S For further information, please contact: Investor Relation

Alk-Abello AS (AKBLF) reports 18% revenue growth in Q2, driven by record tablet sales exceeding DKK1 billion, and raises full-year revenue outlook to 14%-16%.

ALK announces the appointment of Jacob Glenting as new Executive Vice President (EVP) and head of Global R&D, effective 1 September 2026. This position has been vacant since February 2026. Jacob Glenting is currently EVP, Corporate, Portfolio & Product Strategy (CPPS) and has been a member of the Executive Leadership Team since 2024. Prior to this, he headed up ALK’s commercial operations in international markets. With more than 25 years of pharmaceutical, business development, and research expe

ALK delivers 18% organic revenue growth with operating profit (EBIT) up 19% in Q2 ALK sustained strong momentum in Q2, with double-digit growth across all regions driven by sales of tablets and anaphylaxis products. Operating profit increased by 19% on sales growth and an improving gross margin, partly offset by increasing investments in R&D and sales and marketing. For the first six months, the EBIT margin was 28%. The full-year revenue outlook has been updated. Performance highlights (Q2) Comp

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the company’s tree pollen tablet (ITULAZAX®) and house dust mite tablet (ACARIZAX®) for children with moderate to severe allergic rhinitis whose symptoms are not controlled by symptomatic treatment. ITULAZAX® is recommended for children aged 5 to 17 with birch pollen allergy and ACARIZAX® for children aged 5 to 11 with house dust mite allergy, making bot

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) will publish its results for the first six months of 2026 in the morning on Thursday, 20 August 2026. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CEST, where ALK’s management will comment on the results for the first six months and the outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. Live au

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced the market launch of neffy® 2 mg in Canada following the approval by Health Canada in April 2026. The launch of this first ever nasal adrenaline spray for emergency treatment of anaphylaxis represents a significant milestone for adults and children (≥30 kg) experiencing potentially life-threatening allergic reactions due to insect stings or bites, foods, medicines and other allergens, as well as anaphylaxis where the cause is not known or

The current standard of care for food allergy focuses on strict avoidance of the offending allergen and the prompt use of an adrenaline auto-injector (AAI) in the event of an allergic reaction. While antihistamines, corticosteroids, and bronchodilators are frequently used to manage associated symptoms, these agents do not treat anaphylaxis and should only be considered adjunctive therapies alongside epinephrine.

Wondering whether ALK-Abelló at DKK266.20 is still reasonably priced, or if the recent optimism has already been baked into the stock. The share price sits at DKK266.20 after returns of 0.4% over the past week, 3.8% over the past month, 17.5% year to date, 46.7% over 1 year, 214.3% over 3 years and 84.1% over 5 years. This naturally raises questions about what is already reflected in the current valuation. Recent coverage has focused on ALK-Abelló's position within pharmaceuticals and...

At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which will this year take part in Istanbul, Türkiye from 12 to 15 June 2026, the Danish pharmaceutical company ALK will present data and key insights within anaphylaxis, food and respiratory allergy. At two ALK symposia, FlashTalk, oral and poster sessions at the EAACI 2026 scientific programme, ALK will present data on real-world use and clinical implementation of nasal adrenaline in anaphylaxis and share

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the company’s Executive Vice President and CFO, Claus Steensen Sølje, is scheduled to present at the 2026 Jefferies Global Healthcare Conference in New York City taking place from 2 - 4 June 2026 on Wednesday, 3 June 2026, at 7.35 AM EDT (13.35 PM CEST). ALK-Abelló A/S For further information, please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 Ab

ALK delivers 18% organic revenue growth with operating profit (EBIT) up 22% in Q1 Q1 saw broad-based growth across key categories and regions with sustained, strong momentum in tablet sales in Europe and North America. Operating profit increased driven by sales growth, improved gross margin, and scale benefits, resulting in an EBIT margin of 32%. Free cash flow doubled. The full-year outlook has been upgraded. Performance highlights Comparative figures for Q1 2025 are shown in brackets. Growth r

Inside Information ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the 2026 full-year financial outlook has been upgraded reflecting a strong underlying momentum for tablet sales and reduced risks associated with price and rebate adjustments in 2026. Revenue is now expected to grow by 13-16% in local currencies (previously 11-15% growth) based on growth across all sales regions and product lines. The EBIT margin is now expected at around 26% (previously 25%). ALK’s long-term financ

ALK-Abelló (CPSE:ALK B) has drawn fresh attention after recent trading data showed a 1.5% daily return and a 7.2% gain over the past week, prompting investors to reassess the allergy specialist. See our latest analysis for ALK-Abelló. That short term strength fits into a wider upswing, with a 30 day share price return of 17.6% and a 1 year total shareholder return of 56.5%, indicating that momentum has been building rather than fading. If this kind of move has you thinking about what else is...

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) will publish its results for the first quarter of 2026 in the morning on Tuesday, 5 May 2026. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CEST, where ALK’s management will comment on the results and outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. Live audio webcast The meeting will be audio

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff: The Board of Directors has previously granted share options and performance shares in ALK-Abelló A/S, re. company release no. 08/2023 of 31 March 2023. The right to share options and performance shares may be achieved in April 2026, provided that ALK achiev

MELBOURNE, Australia and OXFORD, United Kingdom, April 08, 2026 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today announces two additions to its Board of Directors, former CEO of ALK-Abello A/S, Carsten Hellmann and former Chief Commercial Officer of Aimmune Therapeutics, Andrew Oxtoby. Collectively, Carsten and Andrew bring to Aravax exceptionally deep experience from the pharmaceutical indust